Interferon beta-1b

DB00068

biotech approved

Deskripsi

Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi * 0.25 to 2,88 L/kg
Klirens (Clearance) * 9.4 – 28.9 mL/min•kg-1 [patients with diseases other than MS receiving single intravenous doses up to 2.0 mg]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid excessive or chronic alcohol consumption. Alcohol and Interferon beta-1 can both cause hepatoxicity, therefore if they are used together they may have additive hepatoxic effects.

Interaksi Obat

655 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon beta-1b.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon beta-1b.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon beta-1b.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon beta-1b.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon beta-1b.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon beta-1b.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon beta-1b.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon beta-1b.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Interferon beta-1b.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Interferon beta-1b.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon beta-1b.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon beta-1b.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon beta-1b.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon beta-1b.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfacon-1.
Rituximab The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rituximab.
Basiliximab The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Basiliximab.
Muromonab The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Muromonab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibritumomab tiuxetan.
Tositumomab The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tositumomab.
Alemtuzumab The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alemtuzumab.
Alefacept The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alefacept.
Efalizumab The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfa-2b.
Daclizumab The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daclizumab.
Phenylalanine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Phenylalanine.
Flunisolide The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Flunisolide.
Bortezomib The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bortezomib.
Cladribine Interferon beta-1b may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carmustine.
Amsacrine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Amsacrine.
Bleomycin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bleomycin.
Chlorambucil The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Chlorambucil.
Raltitrexed The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Raltitrexed.
Mitomycin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mitomycin.
Bexarotene The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bexarotene.
Vindesine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vindesine.
Floxuridine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Floxuridine.
Indomethacin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Indomethacin.
Tioguanine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tioguanine.
Vinorelbine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vinorelbine.
Dexrazoxane The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexrazoxane.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Beclomethasone dipropionate.
Sorafenib The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sorafenib.
Streptozocin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Streptozocin.
Trifluridine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trifluridine.
Gemcitabine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gemcitabine.
Betamethasone The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Betamethasone.
Teniposide The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Teniposide.
Epirubicin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Epirubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Chloramphenicol.
Lenalidomide The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Lenalidomide.
Altretamine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Altretamine.
Zidovudine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Zidovudine.
Cisplatin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cisplatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Oxaliplatin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cyclophosphamide.
Vincristine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vincristine.
Fluorouracil The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluorouracil.
Propylthiouracil The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methotrexate.
Carbamazepine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carbamazepine.
Vinblastine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Linezolid.
Imatinib The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Imatinib.
Triamcinolone The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daunorubicin.
Irinotecan The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Melphalan.

Target Protein

Interferon alpha/beta receptor 1 IFNAR1
Interferon alpha/beta receptor 2 IFNAR2

Referensi & Sumber

Synthesis reference: Heinz-Jurgen Friesen, Sidney Pestka, "Preparation of homogeneous human fibroblast interferon." U.S. Patent US4289689, issued December, 1968.
Artikel (PubMed)
  • PMID: 9890522
    Lin L: Betaseron. Dev Biol Stand. 1998;96:97-104.
Link

Contoh Produk & Brand

Produk: 22 • International brands: 0
Produk
  • Betaferon
    Injection, powder, for solution • 0.25 mg/ml • Subcutaneous • EU • Approved
  • Betaferon
    Injection, powder, for solution • 0.25 mg/ml • Subcutaneous • EU • Approved
  • Betaferon
    Injection, powder, for solution • 0.25 mg/ml • Subcutaneous • EU • Approved
  • Betaferon
    Injection, powder, for solution • 0.25 mg/ml • Subcutaneous • EU • Approved
  • Betaferon
    Injection, powder, for solution • 0.25 mg/ml • Subcutaneous • EU • Approved
  • Betaferon
    Injection, powder, for solution • 0.25 mg/ml • Subcutaneous • EU • Approved
  • Betaferon
    Injection, powder, for solution • 0.25 mg/ml • Subcutaneous • EU • Approved
  • Betaferon
    Injection, powder, for solution • 0.25 mg/ml • Subcutaneous • EU • Approved
Menampilkan 8 dari 22 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul